EVINE Live Inc. (EVLV) Reaches $0.33 Yearly Low; American Physicians Service Group (AMPH) Has 1.86 Sentiment


The stock of EVINE Live Inc. (NASDAQ:EVLV) hit a new 52-week low and has $0.30 target or 9.00% below today’s $0.33 share price. The 7 months bearish chart indicates high risk for the $22.40M company. The 1-year low was reported on Mar, 17 by Barchart.com. If the $0.30 price target is reached, the company will be worth $2.02M less. The stock decreased 4.84% or $0.0168 during the last trading session, reaching $0.33. About 261,310 shares traded. EVINE Live Inc. (NASDAQ:EVLV) has declined 56.61% since March 17, 2018 and is downtrending. It has underperformed by 60.98% the S&P500. Some Historical EVLV News: 27/03/2018 – Evine Names Alex Spiro as Director and Board Member; 30/05/2018 – EVINE Live 1Q Loss/Shr 5c; 11/04/2018 – Evine Names Diana Purcel as Chief Financial Officer; 14/03/2018 – EVINE Live Sees FY18 EBIT $19M-EBIT $21M; 19/03/2018 – Evine Live Adds Mark Locks to Its Executive Team; 30/05/2018 – EVINE LIVE 1Q GROSS MARGIN +35.9%, EST. +36.1%; 20/03/2018 – Evine Partners with Cosmopolitan to Explore Intimacy, Relationships and Empowerment During a Special “Evine After Dark” Edi; 30/04/2018 – Evine Expands Studio and Office Space in Los Angeles and New York City Markets; 19/04/2018 – Waterford Crystal to Celebrate 11th Anniversary with Evine During a Live Broadcast in Ireland; 18/04/2018 – Private Capital Advisors Inc. Exits Position in Evine Live

American Physicians Service Group Inc (AMPH) investors sentiment increased to 1.86 in Q4 2018. It’s up 0.86, from 1 in 2018Q3. The ratio is positive, as 67 active investment managers opened new and increased stock positions, while 36 sold and trimmed holdings in American Physicians Service Group Inc. The active investment managers in our database now own: 22.11 million shares, up from 20.26 million shares in 2018Q3. Also, the number of active investment managers holding American Physicians Service Group Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 33 Increased: 39 New Position: 28.

EVINE Live Inc. operates as a multiplatform video commerce firm in the United States. The company has market cap of $22.40 million. The firm markets, sells, and distributes products to clients through television, online, mobile, and social media in various merchandise categories, such as jewelry and watches, which include silver, gold, and gemstones to simulated diamonds; home and consumer electronics, which include home décor, bed and bath textiles, cookware, kitchen electrics, mattresses, tabletop accessories, and home furnishings; beauty products, including skincare, cosmetics, hair care, and bath and body products; and fashion and accessories, such as apparel, outerwear, intimates, handbags, accessories, and footwear. It currently has negative earnings. It has access to approximately 87 million cable and satellite television homes, as well as offers its products through online at evine.com.

More notable recent EVINE Live Inc. (NASDAQ:EVLV) news were published by: Globenewswire.com which released: “Evine Live Inc. Reports Preliminary Fourth Quarter 2018 Results – GlobeNewswire” on March 06, 2019, also Nasdaq.com with their article: “Live TV from the Middle of the Ocean? Evine Sets Sail with Invicta Watches! – Nasdaq” published on February 19, 2019, Nasdaq.com published: “Evine Strengthens Fashion and Accessories Division with Addition of Former Target Vice President – Nasdaq” on February 20, 2019. More interesting news about EVINE Live Inc. (NASDAQ:EVLV) were released by: Globenewswire.com and their article: “Evine Live Inc. Reports Third Quarter 2018 Results – GlobeNewswire” published on November 28, 2018 as well as Seekingalpha.com‘s news article titled: “Evine: 70% Upside This Year – Seeking Alpha” with publication date: June 06, 2018.

Among 3 analysts covering EVINE Live (NASDAQ:EVLV), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. EVINE Live has $1.2500 highest and $0.5 lowest target. $0.92’s average target is 178.79% above currents $0.33 stock price. EVINE Live had 3 analyst reports since November 29, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, March 7 by DA Davidson. The firm earned “Buy” rating on Thursday, November 29 by FBR Capital. Craig Hallum maintained EVINE Live Inc. (NASDAQ:EVLV) on Thursday, March 7 with “Buy” rating.

Eam Investors Llc holds 0.66% of its portfolio in Amphastar Pharmaceuticals, Inc. for 122,250 shares. Cortina Asset Management Llc owns 333,483 shares or 0.41% of their US portfolio. Moreover, Argent Capital Management Llc has 0.24% invested in the company for 235,350 shares. The New York-based Rothschild & Co Asset Management Us Inc. has invested 0.08% in the stock. Federated Investors Inc Pa, a Pennsylvania-based fund reported 1.36 million shares.

The stock decreased 1.32% or $0.27 during the last trading session, reaching $20.23. About 368,775 shares traded or 66.52% up from the average. Amphastar Pharmaceuticals, Inc. (AMPH) has risen 36.93% since March 17, 2018 and is uptrending. It has outperformed by 32.56% the S&P500. Some Historical AMPH News: 12/03/2018 – Amphastar Pharmaceuticals 4Q Adj EPS 10c; 12/03/2018 – Amphastar Pharmaceuticals 4Q Rev $60.4M; 09/05/2018 – Amphastar Pharmaceuticals 1Q Adj Loss/Shr 5c; 09/05/2018 – Amphastar Short-Interest Ratio Rises 78% to 18 Days; 21/03/2018 – AMPHASTAR REPORTS FINAL JUDGMENT IN PATENT LITIGATION VS MOMENT; 13/03/2018 – AMPHASTAR PHARMACEUTICALS INC AMPH.O : BMO RAISES TARGET PRICE TO $19 FROM $17; 09/05/2018 – Amphastar Pharmaceuticals 1Q Rev $58.4M; 02/05/2018 – Amphastar Closes Below 50-Day Moving Average: Technicals; 19/04/2018 – DJ Amphastar Pharmaceuticals Inc, Inst Holders, 1Q 2018 (AMPH); 10/05/2018 – Amphastar Closes Below 200-Day Moving Average: Technicals

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $943.35 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

More notable recent Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news were published by: Nasdaq.com which released: “MNK vs. AMPH: Which Stock Should Value Investors Buy Now? – Nasdaq” on March 08, 2019, also Nasdaq.com with their article: “After-Hours Earnings Report for March 12, 2019 : ZTO, BTG, AMPH, NTRA, COHU, CARA, EVRI, SENS, APEI, RC, TISI, CLNE – Nasdaq” published on March 12, 2019, Seekingalpha.com published: “Needham softens view on Amphastar in premarket analyst action – Seeking Alpha” on March 13, 2019. More interesting news about Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) were released by: Benzinga.com and their article: “(AMPH) – Amphastar Pharmaceutical Q4 Earnings Preview – Benzinga” published on March 12, 2019 as well as Seekingalpha.com‘s news article titled: “Akari Therapeutics leads healthcare gainers; Verastem and Seelos Therapeutics among losers – Seeking Alpha” with publication date: March 13, 2019.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Ratings Chart